Market Research Report
Hepatitis B: Competitive Landscape to 2027
|Published by||GlobalData||Product code||859668|
|Published||Content info||49 Pages
Delivery time: 1-2 business days
|Hepatitis B: Competitive Landscape to 2027|
|Published: May 31, 2019||Content info: 49 Pages||
Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable hepatitis B surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC).
Within the next ten years, up to six new drugs are projected to be approved for the treatment of chronic hepatitis B virus (HBV) infections in the eight major markets (8MM - US, Germany, France, Italy, Spain, the UK, Japan, and China) The HBV pipeline is heavily weighted towards small molecules and vaccines, which make up almost 60% of the drugs currently under development.
Asia-Pacific leads in HBV clinical trials; with 263 ongoing trials and China has the most drugs in the pipeline. Due to the high prevalence of chronic HBV in China, multiple companies are developing therapies specifically targeted at this market.
Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV. There is no cure for chronic HBV infections, but recent success in the cure of hepatitis C has re-energized the field. The HBV pipeline is highly active, with 176 products in all stages of development, and 85% of those drugs are in early stages. Gilead Sciences is the only company that has a solid presence in HBV with its brands Viread and Vemlidy, as well as a strong pipeline featuring 36 active clinical trials.
There is a high unmet need in the finite duration of treatment with oral therapies. These drugs suppress the infection rather than eradicate it, so a new therapy that could enhance the control of the virus and long-term viral suppression would be highly advantageous.
The report "Hepatitis B: Competitive Landscape to 2027" provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Overall, it is expected that the new drug approvals would improve the treatment options of Hepatitis B over the next decade (2017-2027).
GlobalData's Hepatitis B: Competitive Landscape to 2027 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include -